OKYO
OKYO Pharma Limited
NASDAQ · Healthcare · Biotechnology · GB
$1.57
+1.29%Jul 23, 2026, 16:00 UTC
OKYO Pharma Non-Executive Director John Brancaccio purchased 5,000 ordinary shares of the company on NASDAQ at $1.48 per share.
Source:Jul 23, 2026, 11:00 UTC
OKYO Pharma CEO Robert J. Dempsey purchased 15,000 ordinary shares on NASDAQ at $1.54 per share.
Source:Jul 8, 2026, 12:35 UTC
OKYO Pharma received positive FDA feedback from a Type D meeting supporting advancement of urcosimod into a Phase 3 trial for neuropathic corneal pain.